Q1 2026 Sartorius AG and Sartorius Stedim Biotech SA Earnings Call Transcript
Key Points
- Sartorius Stedim Biotech SA (SDMHF) reported a strong start to 2026 with sales revenue increasing by 7.9% in constant currencies.
- The company's recurring consumables business showed robust demand, contributing significantly to growth.
- The underlying EBITDA margin remained resilient at 30.7%, despite some mix effects and tariff impacts.
- Strong cash flow generation was observed, with operating cash flow increasing by over 61% year-on-year.
- The company maintained a solid equity ratio of 50.6%, reflecting a strong capital structure and financial flexibility.
- Equipment sales were softer in Q1 due to customer delivery schedules, although improvement is expected in Q2.
- The underlying EBITDA margin was flat year-over-year, impacted by less favorable product mix and tariff effects.
- There was a technical margin drag due to an increase in the Sartorius branding fee charge.
- The company faces geopolitical and macroeconomic uncertainties, particularly related to energy prices and geopolitical tensions.
- FX headwinds are anticipated to impact the financials, with a projected negative effect of around 2 percentage points for the full year.
Ladies and gentlemen, welcome to the Sartorius and Sartorius Stedim Biotech conference call and live webcast on Q1 2026. I'm your chorus call operator. (Operator Instructions). I would now like to turn the conference over to Petra Muller, Head of Investor Relations of Sartorius. Please go ahead.
Thank you. Hello, and a welcome also from my side. I'm joined today by our CEO, Michael Grosse; Florian Funck, our CFO, by Rene Faber, Head of the Bioprocessing division and CEO of Sartorius Biotech; and by Alexandra Gatzemeyer, Head of our LPS division.
As always, we will start with prepared remarks followed by the Q&A session. As the call is scheduled to one hour, please limit your question to one so that as many participants as possible can take part. Please note that management's comments during this call will include forward-looking statements that involve risks and uncertainties. For a discussion of risk factors, I encourage you to review the safe harbor statement contained in today's press
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
